First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Ph+ ALL
Expert Elias Jabbour, MD, reviews clinical data from the PhALLCON study of ponatinib vs imatinib in patients with Ph+ acute lymphocytic leukemia and considers its clinical implications.
Elias Jabbour First Report Comparing Ponatinib Newly Diagnosed Acute Lymphocytic Leukemia Call Cancer
Source: onclive.com